Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use RYPLAZIM® safely and effectively. See full prescribing information for RYPLAZIM. RYPLAZIM® (plasminogen, human-tvmh) lyophilized powder for reconstitution, for intravenous use Initial U.S. Approval: 2021
Medication labelWhy this: Advisory · dailymed-other
RYPLAZIM® (plasminogen, human-tvmh) is plasma-derived human plasminogen indicated for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia).
- generic_name
- plasminogen
- product_names
- plasminogen
- ndc
- 70573-099, 70573-099-01, 70573-099-02
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en